April 7: The Week in Cancer News
New therapy approved for locally advanced or metastatic bladder cancer, and court ruling could lead to cost hikes for certain cancer screenings.
Progress Against Cancer
New therapy approved for locally advanced or metastatic bladder cancer, and court ruling could lead to cost hikes for certain cancer screenings.
The researchers are interested in understanding why some lesions turn into pancreatic cancer to better identify those with a high risk of the disease. A surprisingly large number of healthy people may be walking...
A targeted therapy is now available for more patients with advanced bladder cancers The U.S. Food and Drug Administration (FDA) has granted accelerated approval to enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for...
Cancer deaths linked to cigarette smoking account for millions of years in lost lives and billions of dollars in economic burden.
Researchers are striving to understand why men are more likely than women to get and die from many types of cancer.
While colorectal cancer incidence has gone down among older people, incidence rates have steadily increased for people under age 50. Younger people are more likely to be diagnosed at a later stage and have unique challenges that come with facing cancer in their prime.
Immunotherapy combination treatments are the first choice for treating many advanced cancers, and more combinations are coming.
A nationwide survey found strong support for complementary therapies like massage and meditation, but also significant barriers to access.
Immunotherapies are poised to change care in advanced endometrial cancer, and more news selected by the editors of Cancer Today.
As we welcome spring, enjoy the latest round of editors’ picks selected by the editors of AACR’s 10 journals. Among this month’s highlights are an analysis of the racial/ethnic and sex-related differences in genomic...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More